NCT03596801View on ClinicalTrials.gov

Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 25, 2018

Primary Completion Date

April 25, 2024

Study Completion Date

April 25, 2024

Conditions
RSV Infection
Interventions
BIOLOGICAL

RSV 6120/∆NS1

Delivered as nose drops

BIOLOGICAL

RSV 6120/F1/G2/∆NS1

Delivered as nose drops

BIOLOGICAL

Placebo

Delivered as nose drops

Trial Locations (1)

21205

Johns Hopkins University Center for Immunization Research, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT03596801 - Evaluating the Infectivity, Safety and Immunogenicity of Respiratory Syncytial Virus Vaccines, RSV 6120/∆NS1 and RSV 6120/F1/G2/∆NS1, in RSV-Seropositive Children and RSV-Seronegative Infants and Children | Biotech Hunter | Biotech Hunter